Are all of the following statements about Sjögren’s syndrome correct: (a) association with lymphoma and pseudolymphoma, (b) association with cryoglobulinemia, (c) anti‑Ro (SSA) and anti‑La (SSB) antibodies are part of the diagnostic criteria, (d) the Schirmer test evaluates dry eyes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

All Statements About Sjögren's Syndrome Are Correct

Yes, all four statements (a-d) regarding Sjögren's syndrome are accurate and well-supported by current clinical guidelines and evidence.

Detailed Analysis of Each Statement

(a) Association with Lymphoma and Pseudolymphoma: TRUE

Sjögren's syndrome carries a significantly elevated risk of lymphoproliferative disorders. Patients are at increased risk for potentially life-threatening lymphoproliferative disorders, with lymphoma developing in approximately 2-5% of patients 1. The guidelines specifically identify this as one of the most serious complications of the disease 2, 3.

  • Patients with decreased C4 levels at diagnosis have a higher risk of developing lymphoma 1
  • The risk represents excess mortality in Sjögren's syndrome, primarily related to systemic involvement and lymphoma development 3
  • Non-Hodgkin's lymphoma of the B-cell series is the predominant type 4

Clinical Pitfall: Monitor patients with hypergammaglobulinemia, positive rheumatoid factor, and cryoglobulins more closely, as these markers correlate with higher lymphoma risk 5.

(b) Association with Cryoglobulinemia: TRUE

Cryoglobulins and hypocomplementemia are recognized as the main prognostic markers in Sjögren's syndrome 6. Cryoglobulins serve as markers of more severe disease and correlate with both lymphoma development and mortality 7.

  • Cryoglobulins indicate a more aggressive disease phenotype
  • Their presence warrants closer monitoring for systemic complications
  • They are part of the immunological profile that helps stratify disease severity

(c) Anti-Ro (SSA) and Anti-La (SSB) Antibodies in Diagnostic Criteria: TRUE

The latest classification criteria explicitly include anti-SSA/Ro antibody positivity as a weighted diagnostic component, scoring 3 points in the diagnostic algorithm 1. The European-American Consensus criteria clearly incorporate these antibodies:

  • Anti-Ro/SSA positivity: 3 points (highest weight among serological markers)
  • Anti-La/SSB: While not separately scored in the 2016 criteria, it is closely associated with anti-Ro/SSA
  • A total score of ≥4 points establishes the diagnosis of primary Sjögren's syndrome 1

Important Nuance: Anti-Ro/SSA is found in approximately 57% of Sjögren's patients, while anti-La/SSB appears in about 42-50% 8, 9. Anti-La/SSB has higher diagnostic specificity (83% of anti-La positive patients have Sjögren's syndrome) compared to anti-Ro alone (only 42% specificity) 9. The presence of both antibodies, particularly anti-La/SSB, identifies patients at higher risk for hypergammaglobulinemia, rheumatoid factor positivity, and lymphoproliferative disorders 5.

(d) Schirmer Test for Dry Eyes: TRUE

The Schirmer test is explicitly included in the diagnostic criteria for Sjögren's syndrome, scoring 1 point when results show ≤5 mm/5 minutes without anesthesia 1. This test directly evaluates aqueous tear production deficiency, which is central to the ocular manifestations of the disease.

  • The test measures tear production by placing filter paper in the lower eyelid
  • Abnormal result: <5 mm in 5 minutes 1
  • It is one of five weighted items in the current classification criteria
  • The test should be performed before instilling any eye drops 2

Clinical Application: The Schirmer test is part of a comprehensive ocular evaluation that also includes tear break-up time, ocular staining scores (van Bijsterveld or Ocular Staining Score), and assessment of tear osmolarity 1, 2.

Diagnostic Algorithm Summary

The current diagnostic approach uses a weighted scoring system where:

  • Anti-Ro/SSA antibodies: 3 points
  • Focal lymphocytic sialadenitis (focus score ≥1): 3 points
  • Abnormal Schirmer test (≤5 mm/5 minutes): 1 point
  • Abnormal ocular staining: 1 point
  • Unstimulated salivary flow ≤0.1 mL/min: 1 point

Diagnosis requires ≥4 points plus symptoms of eye/mouth dryness for ≥3 months 1.

Critical Management Considerations

Given the associations mentioned in statements (a) and (b), patients require:

  • Co-management with rheumatology for systemic complications 2, 1
  • Regular monitoring for lymphoproliferative disorders, especially in those with cryoglobulins, low C4, hypergammaglobulinemia, or positive rheumatoid factor 1, 5
  • Interdisciplinary care addressing both local sicca symptoms and systemic manifestations 4

References

3
Research

Sjögren syndrome.

Nature reviews. Disease primers, 2016

4
Research

The Diagnosis and Treatment of Sjögren's Syndrome.

Deutsches Arzteblatt international, 2017

9
Research

Anti-La (SS-B): a diagnostic criterion for Sjögren's syndrome?

Clinical and experimental rheumatology, 1989

Related Questions

What is the recommended diagnostic workup and treatment plan for Sjögren syndrome?
Do you monitor C-reactive protein (CRP) levels in Sjögren's syndrome?
Which of the following manifestations are associated with primary Sjögren's syndrome: corneal ulceration, Fanconi syndrome, lymphoma, amyloidosis, or dental caries?
What is the significance of a positive anti-SSB (Sjögren's syndrome B) antibody test?
Are Sjogren's syndrome and burning mouth disease the same condition?
What alternative anxiolytic agents are appropriate for a patient currently using pregabalin for anxiety?
What is the best alternative therapy for painful diabetic peripheral neuropathy in a patient who cannot use duloxetine or pregabalin?
What alternative medications can be used to treat anxiety in a patient who experienced insomnia with selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs)?
How does buspirone work in an anxiety patient who developed insomnia on SSRIs and SNRIs?
In an adult with type 2 diabetes, does empagliflozin lead to greater weight loss than dapagliflozin?
Should a patient with mitral valve prolapse and no history of rheumatic fever receive antibiotic prophylaxis (amoxicillin) before dental procedures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.